Trial · NCT07106528
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
NCT07106528, Phase 2, Phase 3, Not yet recruiting, Peking Union Medical College Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer. Trials, record NCT07106528. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07106528
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
- NCT number
- NCT07106528
- Status
- Not yet recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 128 participants, estimated
- Lead sponsor
- Peking Union Medical College Hospital
- Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Small Cell Lung Cancer ( SCLC )
- Interventions
- Organoid Drug Sensitivity Testing-Guided Therapy, Topotecan
- First posted
- 2025-08-06
- Last updated
- 2025-08-06
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) | From date of randomization until the date of first documented progression (RECIST v1.1) or death from any cause, whichever occurs first, assessed up to 100 months. | From the date of randomization to the date of first recording of disease progression ( RECIST v1.1 ) or all-cause death, whichever occurred first. |
| Secondary | Overall Survival (OS) | From date of randomization until the date of death from any cause, assessed up to 100 months. | From date of randomization until the date of death from any cause |
| Secondary | Objective Response Rate (ORR) | From date of randomization until the date of first documented progression, assessed by RECIST v1.1 criteria at 6- to 8-week intervals up to 100 months. | From date of randomization until the date of first documented progression, assessed by RECIST v1.1 criteria at 6- to 8-week |
| Secondary | Duration of Response (DOR) | From date of first documented objective response (CR or PR per RECIST v1.1) until the date of first documented progression or death from any cause, whichever occurs first, assessed up to 100 months. | From date of first documented objective response (CR or PR per RECIST v1.1) until the date of first documented progression or death from any cause, whichever occurs first |
| Secondary | Grade ≥3 Adverse Events | From date of first treatment administration until 3 months after last dose, assessed by CTCAE v5.0 criteria. | The incidence of treatment-related adverse events ≥ grade 3 ( CTCAE v5.0 ). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07106528
GET https://conductscience.org/api/trials/v1/NCT07106528/registered